|
1
|
Benton CB, Nazha A, Pemmaraju N and
Garcia-Manero G: Chronic myelomonocytic leukemia: Forefront of the
field in 2015. Crit Rev Oncol Hematol. 95:222–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chavez-Gonzalez A, Bakhshinejad B,
Pakravan K, Guzman ML and Babashah S: Novel strategies for
targeting leukemia stem cells: sounding the death knell for blood
cancer. Cell Oncol. 40:1–20. 2017. View Article : Google Scholar
|
|
3
|
Calado RT and Young NS: Telomere
maintenance and human bone marrow failure. Blood. 111:4446–4455.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Safe S, Jin UH, Hedrick E, Reeder A and
Lee SO: Minireview: Role of orphan nuclear receptors in cancer and
potential as drug targets. Mol Endocrinol. 28:157–172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen BA, Huang ZH, Zhang XP, Ou-Yang J, Li
JY, Zhai YP, Sun XM, Xu YL, Lu Q, Wang JM, et al: An
epidemiological investigation of leukemia incidence between 2003
and 2007 in Nanjing, China. J Hematol Oncol. 3:212010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Welch HG and Larson EB: Cost effectiveness
of bone marrow transplantation in acute nonlymphocytic leukemia. N
Engl J Med. 321:807–812. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lenarsky C and Parkman R: Bone marrow
transplantation for the treatment of immune deficiency states. Bone
Marrow Transplant. 6:361–369. 1990.PubMed/NCBI
|
|
8
|
Godder KT, Abhyankar SH, Lamb LS, Best RG,
Geier SS, Pati AR, Gee AP and Henslee-Downey PJ: Donor leukocyte
infusion for treatment of graft rejection post partially mismatched
related donor bone marrow transplant. Bone Marrow Transplant.
22:111–113. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kobayashi T, Yoshida J, Ishiyama J, Noda
S, Kito A and Kida Y: Combination chemotherapy with cisplatin and
etoposide for malignant intracranial germ-cell tumors. An
experimental and clinical study. J Neurosurg. 70:676–681. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borst P, Rottenberg S and Jonkers J: How
do real tumors become resistant to cisplatin? Cell Cycle.
7:1353–1359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wong E and Giandomenico CM: Current status
of platinum-based antitumor drugs. Chem Rev. 99:2451–2466. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Milacic V, Fregona D and Dou QP: Gold
complexes as prospective metal-based anticancer drugs. Histol
Histopathol. 23:101–108. 2008.PubMed/NCBI
|
|
13
|
Chen H, Hardy TM and Tollefsbol TO:
Epigenomics of ovarian cancer and its chemoprevention. Front Genet.
2:672011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu Y, Bhattacharyya D, King CL,
Baskerville-Abraham I, Huh SH, Boysen G, Swenberg JA, Temple B,
Campbell SL and Chaney SG: Solution structures of a DNA dodecamer
duplex with and without a cisplatin 1,2-d(GG) intrastrand
cross-link: Comparison with the same DNA duplex containing an
oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry.
46:6477–6487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Podratz JL, Knight AM, Ta LE, Staff NP,
Gass JM, Genelin K, Schlattau A, Lathroum L and Windebank AJ:
Cisplatin induced mitochondrial DNA damage in dorsal root ganglion
neurons. Neurobiol Dis. 41:661–668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oakes SA and Korsmeyer SJ: Untangling the
web: Mitochondrial fission and apoptosis. Dev Cell. 7:460–462.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Szabadkai G, Simoni AM, Chami M,
Wieckowski MR, Youle RJ and Rizzuto R: Drp-1-dependent division of
the mitochondrial network blocks intraorganellar Ca2+
waves and protects against Ca2+-mediated apoptosis. Mol
Cell. 16:59–68. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shaw JM and Nunnari J: Mitochondrial
dynamics and division in budding yeast. Trends Cell Biol.
12:178–184. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wan YY, Zhang JF, Yang ZJ, Jiang LP, Wei
YF, Lai QN, Wang JB, Xin HB and Han XJ: Involvement of Drp1 in
hypoxia-induced migration of human glioblastoma U251 cells. Oncol
Rep. 32:619–626. 2014.PubMed/NCBI
|
|
20
|
Chan DC: Mitochondrial fusion and fission
in mammals. Annu Rev Cell Dev Biol. 22:79–99. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Santin G, Piccolini VM, Barni S, Veneroni
P, Giansanti V, Dal Bo V, Bernocchi G and Bottone MG: Mitochondrial
fusion: A mechanism of cisplatin-induced resistance in
neuroblastoma cells? Neurotoxicology. 34:51–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Farrand L, Byun S, Kim JY, Im-Aram A, Lee
J, Lim S, Lee KW, Suh JY, Lee HJ and Tsang BK: Piceatannol enhances
cisplatin sensitivity in ovarian cancer via modulation of p53,
X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial
fission. J Biol Chem. 288:23740–23750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kato S, Ideguchi H, Muta K, Nishimura J
and Nawata H: Mechanisms involved in the development of adriamycin
resistance in human leukemic cells. Leuk Res. 14:567–573. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zwelling LA, Michaels S, Schwartz H,
Dobson PP and Kohn KW: DNA cross-linking as an indicator of
sensitivity and resistance of mouse L1210 leukemia to
cis-diamminedichloroplatinum(II) and
L-phenylalanine mustard. Cancer Res. 41:640–649.
1981.PubMed/NCBI
|
|
25
|
Horvathova K, Novotny L and Vachalkova A:
The free radical scavenging activity of four flavonoids determined
by the comet assay. Neoplasma. 50:291–295. 2003.PubMed/NCBI
|
|
26
|
Choi YM, Kim HK, Shim W, Anwar MA, Kwon
JW, Kwon HK, Kim HJ, Jeong H, Kim HM, Hwang D, et al: Mechanism of
cisplatin-induced cytotoxicity is correlated to impaired metabolism
due to mitochondrial ROS generation. PLoS One. 10:e01350832015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaushal GP, Kaushal V, Hong X and Shah SV:
Role and regulation of activation of caspases in cisplatin-induced
injury to renal tubular epithelial cells. Kidney Int. 60:1726–1736.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bai J, He A, Huang C, Yang J, Zhang W,
Wang J, Yang Y, Zhang P, Zhang Y and Zhou F: Serum peptidome based
biomarkers searching for monitoring minimal residual disease in
adult acute lymphocytic leukemia. Proteome Sci. 12:492014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muggia F: Platinum compounds 30 years
after the introduction of cisplatin: Implications for the treatment
of ovarian cancer. Gynecol Oncol. 112:275–281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Prestayko AW, D'Aoust JC, Issell BF and
Crooke ST: Cisplatin (cis-diamminedichloroplatinum II).
Cancer Treat Rev. 6:17–39. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lebwohl D and Canetta R: Clinical
development of platinum complexes in cancer therapy: An historical
perspective and an update. Eur J Cancer. 34:1522–1534. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Galanski M: Recent developments in the
field of anticancer platinum complexes. Recent Patents Anticancer
Drug Discov. 1:285–295. 2006. View Article : Google Scholar
|
|
33
|
Chen H and Chan DC: Physiological
functions of mitochondrial fusion. Ann NY Acad Sci. 1201:21–25.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Renault TT, Floros KV, Elkholi R, Corrigan
KA, Kushnareva Y, Wieder SY, Lindtner C, Serasinghe MN, Asciolla
JJ, Buettner C, et al: Mitochondrial shape governs BAX-induced
membrane permeabilization and apoptosis. Mol Cell. 57:69–82. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Brooks C, Wei Q, Feng L, Dong G, Tao Y,
Mei L, Xie ZJ and Dong Z: Bak regulates mitochondrial morphology
and pathology during apoptosis by interacting with mitofusins. Proc
Natl Acad Sci USA. 104:11649–11654. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Whelan RS, Konstantinidis K, Wei AC, Chen
Y, Reyna DE, Jha S, Yang Y, Calvert JW, Lindsten T, Thompson CB, et
al: Bax regulates primary necrosis through mitochondrial dynamics.
Proc Natl Acad Sci USA. 109:6566–6571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wen S, Zhu D and Huang P: Targeting cancer
cell mitochondria as a therapeutic approach. Future Med Chem.
5:53–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tanaka A and Youle RJ: A chemical
inhibitor of DRP1 uncouples mitochondrial fission and apoptosis.
Mol Cell. 29:409–410. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Han XJ, Yang ZJ, Jiang LP, Wei YF, Liao
MF, Qian Y, Li Y, Huang X, Wang JB, Xin HB, et al: Mitochondrial
dynamics regulates hypoxia-induced migration and antineoplastic
activity of cisplatin in breast cancer cells. Int J Oncol.
46:691–700. 2015.PubMed/NCBI
|
|
40
|
Kim H, Lee JY, Park KJ, Kim WH and Roh GS:
A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial
fragmentation and attenuates kainic acid-induced hippocampal cell
death. BMC Neurosci. 17:332016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Akita M, Suzuki-Karasaki M, Fujiwara K,
Nakagawa C, Soma M, Yoshida Y, Ochiai T, Tokuhashi Y and
Suzuki-Karasaki Y: Mitochondrial division inhibitor-1 induces
mitochondrial hyperfusion and sensitizes human cancer cells to
TRAIL-induced apoptosis. Int J Oncol. 45:1901–1912. 2014.PubMed/NCBI
|
|
42
|
Han XJ, Lu YF, Li SA, Kaitsuka T, Sato Y,
Tomizawa K, Nairn AC, Takei K, Matsui H and Matsushita M: CaM
kinase I alpha-induced phosphorylation of Drp1 regulates
mitochondrial morphology. J Cell Biol. 182:573–585. 2008.
View Article : Google Scholar : PubMed/NCBI
|
